Dr. Kwanten (Belgium) discusses the role of pathophysiological role of intrahepatic vasculature in non-alcoholic fatty liver disease (NAFLD). He mentions that portal hypertension is present in patients with NAFLD and
Dr. Castera discusses how clinicians can integrate NASH assessment and management into the care of diabetic patients in order to provide a holistic approach for the patient for improved patient
Patients and physicians have to know that NASH increases the risk to develop cancers. Specific surveillance has to be implemented when indicated. Hepatocellular carcinoma is rare in patients with NASH
The best treatment for NASH still remains as caloric intake reduction, weight loss, exercise and no heavy alcohol consumption, but these are merely lifestyle changes. There appears to be a
Several cognitive and psychological factors influence behavioral change and weight loss success. Most patients with NAFLD have adverse cognitive-behavioral profiles and 20-25% have co-existing mental illness. Without targeted intervention, behavior
NASH with severe fibrosis is more prevalent than one may think. Hispanics and those with type 2 DM are at a higher risk, however other ethnic groups with risk factors
It was found that the natural history of NAFLD is variable. Whilst 31% of patients with NAFLD develop NASH, 29% of patients have been found to resolve it. The fibrosis
Coexistent steatosis and related metabolic factors, including obesity and DM, exacerbate liver injury in patients with another chronic liver disease and may be risk factors for the development of severe
Systemic effects of obesity on cancer development are especially relevant to the liver and involve inflammation, genetics, growth factors, adipokines and microbiomes among others. NASH’s immune milieu is distinct and
SEARCH
POPULAR VIDEOS
VIDEO CATEGORIES
LAST COMMENTED ARTICLES
